Treat Alzheimer's Disease Differently with Generic Namenda Memantine Drug
Title: Treat Alzheimer’s Disease Differently with Generic Namenda Memantine Drug
Memantine Hydrochloride under the trade name Namenda is a medication administered by mouth for addressing patients with Alzheimer's disease. This particular ailment is a progressive form of presenile dementia that is related to senile dementia except that it normally starts in the age of 40s or 50s. Its first symptoms are impaired memory which is succeeded by impaired thinking and speech and eventually complete helplessness.
Class of Drug
We’ll now see how generic Namenda is dissimilar to other drugs, treating the same Alzheimer’s disease. Other medicines applied for Alzheimer's disease have an effect on acetylcholine which is a neurotransmitter and a derivative of choline (a B-complex vitamin) discharged at the ends of nerve fibers in the bodily and parasympathetic nervous systems. The neurons in the brain use acetylcholine to communicate with one another. These medications include Aricept (Donepezil), Cognex (Tacrine), Razadyne (Galantamine), and Exelon (Rivastigmine). They usually work by inhibiting the enzyme called acetylcholinesterase that demolishes acetylcholine, by that means rising the upshots of acetylcholine. However, generic Namenda (Memantine HCl) acts upon Alzheimer’s disease without involving acetylcholine and acetylcholinesterase in its mechanism of action.
Mechanism of Action
Glutamate is the chief excitant neurochemical present in the brain. It is thought that excess stimulation of neurons or nerve cells by glutamate may be accountable for the devolution of nerves that happens in some neurological disorders, for instance Alzheimer's disease. Glutamate is quite similar to other neurotransmitters as it is generated and discharged by nerve cells in the brain. After its discharge, glutamate moves to neighboring nerve cells where it accompanies a receptor or sense organ on the surface of the cells named the N-methyl-D-aspartate (NMDA). Memantine HCl begins its work by blocking the receptor, thereby reducing the impacts of glutamate. The thinking behind this action is that by hindering the NMDA receptor and the impacts of glutamate, generic Namenda may save nerve cells from superfluous arousal by glutamate. The US Food and Drug Administration (FDA) extended its approval for Memantine in October, 2003.
Generic Namenda (Memantine) is indicated for the treatment Alzheimer’s disease that ranges from moderate to severe dementia (mental deterioration). You can categorize dementia into 3 stages in terms of its severity. The first stage is mild where patients are lively and conducive to companionship with others, but memory loss sets out to hamper their day-by-day life. Moderate dementia which is the second stage is often regarded as the most prolonged stage of the ailment with decline in understanding, common sense, demeanor, and function. Lastly, severe dementia results in loss of long-standing memory and speech. In this stage, sufferers may necessitate round-the-clock attention and can no longer carry out essential self-care activities such as laundering, eating, and utilizing the lavatory.
Generally, the initial dose of generic Namenda is 5 mg once everyday. The dosage is then increased to 5 mg two times daily, and then 5 mg and 10 mg as individual doses on a daily basis. Ultimately, Namenda is administered in 10 mg strength twice daily. It can be swallowed using a full glass of water, with or without meals.